Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369470 | 0.78 | HPGD (0.38) | MAPTGAARAB9ANPSR1 | |
| SCHEMBL7439040 | 0.67 | L3MBTL1 (0.49) | L3MBTL1ADRB1HSP90AA1MGLLALDH1A1 | |
| Iodide SCHEMBL27085269 | 0.67 | L3MBTL1 (0.41) | L3MBTL1ADRB1HSP90AA1MGLLALDH1A1 | |
| SCHEMBL6654238 | 0.66 | LTA4H (0.41) | MGLLTSHR | |
| SCHEMBL22994399 | 0.65 | L3MBTL1 (0.46) | L3MBTL1ADRB1HSP90AA1MGLLALDH1A1 | |
| SCHEMBL25059367 | 0.64 | ADRB1 (0.45) | L3MBTL1ADRB1HSP90AA1MGLLALDH1A1 | |
| SCHEMBL9715330 | 0.64 | ADRB1 (0.62) | L3MBTL1ADRB1HSP90AA1MGLLALDH1A1 | |
| SCHEMBL10373770 | 0.64 | ADRB1 (0.74) | L3MBTL1ADRB1ALDH1A1KCNH2MAPT | |
| SCHEMBL11103700 | 0.64 | ADRB1 (0.74) | L3MBTL1ADRB1ALDH1A1KCNH2MAPT | |
| SCHEMBL9855189 | 0.63 | L3MBTL1 (0.53) | L3MBTL1ADRB1HSP90AA1MGLLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | L3MBTL1 4747/4885ADRB1 33/4885HSP90AA1 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.